Y-mAbs Announces Naxitamab Update 28 October 2019
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq:... Read more
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq:... Read more
EuropaBio hosts 12th annual Industrial Biotech and Bioeconomy Conference – #EFIB2019 As the new... Read more
The BRIDGE – Translational Excellence Programme is seeking mentor teams who wish to combine their research... Read more
Kim Stratton to succeed Anders Hinsby, effective October 1, 2019 Copenhagen, July 15, 2019 – Orphazyme... Read more
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)... Read more
Brussels, 2 July 2019 Today, as the new European Parliament meets for its inaugural session in Strasbourg,... Read more
NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB)... Read more
NEW YORK, July 01, 2019 Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB)... Read more
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”)... Read more